Business

Nycomed says that it is now marketing its Omnaris ciclesonide nasal spray for the treatment of allergic rhinitis in the United Arab Emirates (UAE). The company, a subsidiary of Takeda, says that it will launch… Read more . . .

Specialty pharmaceutical manufacturer Hi-Tech Pharmacal will pay a total of $2.5 million plus up to to $1.75 million in royalties to Dynova Laboratories for a line of homeopathic nasal sprays including the Sinus Buster and… Read more . . .

On March 1, Judge John Koeltl of the US District Court for the Southern District of New York issued a partial summary judgment in Mylan’s patent infringement suit against Sunovion Pharmaceuticals, invalidating 5 of the… Read more . . .

A company called GSC Products has launched what it says is “the world’s first caffeine nasal spray” in the US. GSC says that the product, called Turbo Snort, was introduced on the Internet in January… Read more . . .

Aradigm has announced that the United States Patent and Trademark Office has issued an additional patent covering several formulations of ciprofloxacin, including the company’s lead product, Pulmaquin dual release ciprofloxacin for inhalation. The patent (US… Read more . . .

Irish nebulizer manufacturer Aerogen has received authorization from the Chinese State Food and Drug Administration (SFDA) to market its Aeroneb Pro and Aeroneb Go vibrating mesh nebulizers in China. The company expects to begin selling… Read more . . .

Alexza Pharmaceuticals, which is developing a number of inhaled drugs using its proprietary Staccato inhaler, will offer 44,000,000 shares of common stock and 44,000,000 warrants to purchase common stock at $0.50 per share for a… Read more . . .

Critical Pharmaceuticals and the University of Nottingham have announced a new partnership for development of a “nano-enabled” intranasal formulation of teriparatide for the treatment of osteoporosis. Funding for the £545,000 collaboration is coming from the… Read more . . .

US pharmaceutical company Acorda Therapeutics President and CEO Ron Cohen has announced that the company is “excited” about an agreement with Neuronex, Inc. that will allow Acorda to acquire the company and its diazepam nasal… Read more . . .